Four multi-kinase inhibitors (MKIs) are FDA-approved for HCC treatment: Sorafenib, Lenvatinib, Regorafenib, and Cabozantinib, each targeting various receptor tyrosine kinases. The gene discussed is NTRK1; the disease is hepatocellular carcinoma.